Binary restenosis
7.4%
Target vessel revascularization 1/24 (4.1%)
Target lesion revascularization 1/26 (3.8%)
Conclusions: EES is associated with a very low incidence of instent stenosis and target lesion revascularization in patients with TCAD. Further studies are needed to determine whether PCI with EES could alter the long term outcome of patients with TCAD. Kanagawa, Japan, 5 Tsuchiya General Hospital, Hiroshima, Japan, 6 Tokai University School of Medicine, Kanagawa, Japan, 7 Sakurabashi Watanabe Hospital, Osaka, Japan, 8 Osaka University Graduate School of Medicine, Osaka, Japan, 9 Sendai Kousei Hospital, Sendai, Japan, 10 Kanto Rosai Hospital, Kawasaki, Japan, 11 Nagoya Daini Red Cross Hospital, Nagoya, Japan, 12 Shizuoka General Hospital, Shizuoka, Japan, 13 Akiru Municipal Medical Center, Tokyo, Japan, 14 The Cardiovascular Institute, Tokyo, Japan, 15 Kurashiki Central Hospital, Kurashiki, Japan Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the antiproliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori stent comparing to Cypher stent in Japanese population by a single blinded 3:2 randomized trial and met the primary endpoint, non inferiority in TVF. This is the first report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to Cypher Sirolimus Eluting stent in Japanese population. Methods: This is the first multicenter single-blinded, 3:2 randomized clinical trial comparing Nobori and Cypher in 335 patients (Nobori 198 : Cypher 137) in Japan. Patients with single de novo up to two native coronary lesions were treated. The primary endpoint was TVF (cardiac death, MI and TVR) rate at 9 months; late loss (LL) and restenosis rate (RR) at 8 months were major secondary angiographic endpoints, while MACE and stent thrombosis were major secondary safety endpoints. Duration of dual antiplatelet therapy (DAPT) was also recorded for all patients. Results: No significant difference between both patient backgrounds was found. TLR free rate of Nobori was 98.8% at 2years and 98.3% at 3years. (Cypher 96.0% and 95.2%). MACE free rate of Nobori was 94.1% at 2years and 92.9% at 3years. (Cypher 93.7% and 92.0%). TVF free rate of Nobori was 92.1% at 2years and 90.9% at 3years. (Cypher 93.7% and 91.1%) . No definite or probable stent thrombosis according to ARC definition were found in both groups. Conclusions: In this first randomized clinical trial of Nobori and Cypher stent in Japanese population, Nobori stent was found non-inferior to Cypher in TVF, the primary endpoint. TLR free rate at 3 years of Nobori tended to be higher than that of Cypher and the differences in TLR free rate between Nobori and Cypher at 2 years and 3years were increased (no statistical significance). MACE and TVF free rate of both stents at three years were comparable. Further long term follow-up up to 5years may suggest longer term safety of Nobori Stent. 
TCT-625 THREE YEAR FOLLOW UP OF A RANDOMIZED COMPARISON OF NOBORI, BIOLIMUS A9 ELUTING STENT(BES) WITH CYPHER, SIROLIMUS ELUTING STENT(SES) FOR CORONARY REVASCULARIZATION IN JAPANESE POPULATION

TCT-626
Impact of Periprocedural Myocardial Infarction on In-Hospital and 2-Year Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
Background:
There are few studies comparing the long-term clinical outcomes of patients (pts) with peri-procedural myocardial infarction (P-MI) with those without P-MI following percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in real world clinical practice. Methods: A total of 1119 pts underwent PCI with DESs between 2004 and 2010 were enrolled (control group, nϭ1006 pts and P-MI group, nϭ113 pts). P-MI was defined as major CK-MB elevation (Ն3X the upper limit of normal [ULN]) after PCI. Results: There were no significant differences between the two groups except P-MI group was more elderly, had more female, longer procedure time, higher number of target vessel and stents. At 6 month routine follow-up angiography, there was no significant difference in mean diameter stenosis %, incidence of binary restenosis and late loss between the two groups. Among the major in-hospital outcomes, cardiac death was higher in P-MI group. At 2-year (follow-up, 89.1%), and the cumulative incidence of total death, cardiac death and total major adverse cardiac events (MACEs) were higher in P-MI group, where as repeat PCI including target lesion revascularization (TLR) and target vessel revascularization (TVR). However, when in-hospital mortality was excluded, the major clinical outcomes were not different between the two groups up to 2 years (table) . Conclusions: P-MI was mainly associated with in-hospital cardiac death following PCI with DES in real world clinical practice. However, P-MI doesn't seem to be an independent predictor for adverse clinical outcomes for long-term period.
TCT-627
Does direct DES stenting reduces restenosis; a randomized comparison of direct stent implantation to stenting with predilation or provisional stenting in elective PCI patients Background: Previous studies were performed to investigate whether a strategy of direct stent implantation without pre-dilatation is associated with a reduced incidence of restenosis, compared to conventional stenting with pre-dilatation. However, none of these studies were performed in the drug-eluting stent era. Therefore the STRESSED (direct Stenting To Reduce REStenosis in Stent Era with Drug elution) study was designed and carried out. Methods: A total of 600 patients with stable or unstable angina pectoris or a recent (Ͻ30 days) myocardial infarction were randomized to direct stenting, stenting after predilatation or a provisional stenting strategy. Primary endpoint was the mean minimal lumen diameter (MLD) at 9 months follow-up angiography. Secondary endpoints were the clinical procedural success defined as angiographic success without major adverse cardiac events (MACE) at 9 months and two years follow-up. 
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